Keynote 224 Results Kite. Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma.

We aimed to assess the efficacy and safety of. In the keynote study, a conventional dose of pembrolizumab, 200 mg iv every 3 weeks, was used in a cohort of patients who had failed or progressed on.